Re-examining interpretations of non-ideal behavior during diagnostic fracture injection tests

AbstractDiagnostic fracture injection tests (DFITs) are performed in low permeability formations to estimate the minimum principal stress, formation pressure, permeability, and other parameters. G-function derivative plots are used for diagnosing fracture closure and “non-ideal” reservoir processes. In this study, we use a discrete fracture network hydraulic fracturing simulator to investigate non-ideal DFIT mechanisms. The simulator fully couples fluid flow with the stresses induced by fracture deformation. DFITs are simulated for six different scenarios: a single hydraulic fracture, multiple fracture strands, opening of transverse fractures, near-wellbore complexity, far-field complexity, and height recession. The results indicate that pressure transient behavior commonly ascribed to “fracture height recession,” “closure of transverse fractures,” and “fracture tip extension” are likely to be misinterpreted by conventional techniques. In previous studies, we found that a curving upward G×dP/dG plot is caused by changing fracture stiffness after closure and that the closure pressure is best picked when G×dP/dG begins to deviate upward. In contrast, the commonly used “tangent” method can significantly underestimate the minimum principal stress. The results of this study confirm those prior results. The results suggest that in most cases, it should be possible to use pump-in/flowback tests to confirm estimates of the minimum principal stress. However, if a flow bottleneck occurs at the wellbore due to near-wellbore complexity, the pump-in/flowback test may be uninterpretable

Flexible Ultrasound Transducer Fixture

Final report and team photo for Project 21 of ME450, Fall 2010 semester.This project involves developing an automated ultrasound transducer positioning system for blood flow monitoring that does not disrupt patient care, minimizes measurement variability and is operator independent.William Weitzel (Nephrology, U of M); Grant Kruger (Mechanical Engineering, U of M)http://deepblue.lib.umich.edu/bitstream/2027.42/86248/1/ME450 Fall2010 Final Report - Project 21 - Flexible Ultrasound Transducer Fixture.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/86248/2/ME450 Fall2010 Team Photo - Project 21 - Flexible Ultrasound Transducer Fixture.jp

The Ox on the Roof (Le Boeuf Sur le Toit)

Program for the third annual RISD Cabaret held in the Cellar of the Providence Art Club. Design and layout by Treva Offutt.https://digitalcommons.risd.edu/liberalarts_cabaret_programs/1002/thumbnail.jp

Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19

Importance: Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence of the association of recent cancer treatment and cancer type with COVID-19 mortality. // Objective: To evaluate whether systemic anticancer treatments (SACTs), tumor subtypes, patient demographic characteristics (age and sex), and comorbidities are associated with COVID-19 mortality. // Design, Setting, and Participants: The UK Coronavirus Cancer Monitoring Project (UKCCMP) is a prospective cohort study conducted at 69 UK cancer hospitals among adult patients (≥18 years) with an active cancer and a clinical diagnosis of COVID-19. Patients registered from March 18 to August 1, 2020, were included in this analysis. // Exposures: SACT, tumor subtype, patient demographic characteristics (eg, age, sex, body mass index, race and ethnicity, smoking history), and comorbidities were investigated. // Main Outcomes and Measures: The primary end point was all-cause mortality within the primary hospitalization. // Results: Overall, 2515 of 2786 patients registered during the study period were included; 1464 (58%) were men; and the median (IQR) age was 72 (62-80) years. The mortality rate was 38% (966 patients). The data suggest an association between higher mortality in patients with hematological malignant neoplasms irrespective of recent SACT, particularly in those with acute leukemias or myelodysplastic syndrome (OR, 2.16; 95% CI, 1.30-3.60) and myeloma or plasmacytoma (OR, 1.53; 95% CI, 1.04-2.26). Lung cancer was also significantly associated with higher COVID-19–related mortality (OR, 1.58; 95% CI, 1.11-2.25). No association between higher mortality and receiving chemotherapy in the 4 weeks before COVID-19 diagnosis was observed after correcting for the crucial confounders of age, sex, and comorbidities. An association between lower mortality and receiving immunotherapy in the 4 weeks before COVID-19 diagnosis was observed (immunotherapy vs no cancer therapy: OR, 0.52; 95% CI, 0.31-0.86). // Conclusions and Relevance: The findings of this study of patients with active cancer suggest that recent SACT is not associated with inferior outcomes from COVID-19 infection. This has relevance for the care of patients with cancer requiring treatment, particularly in countries experiencing an increase in COVID-19 case numbers. Important differences in outcomes among patients with hematological and lung cancers were observed